Tesofensine Dosage Chart & Schedule
Tesofensine is an orally active small-molecule triple monoamine reuptake inhibitor first trialed for neurodegenerative disease and later repurposed for obesity. It is not a peptide. It remains investigational and is not FDA-approved, though it produced notable weight loss in Phase 2 obesity trials.
Tesofensine is an orally active small-molecule triple monoamine reuptake inhibitor studied for obesity, and it is not a peptide. Phase 2 obesity trials reported roughly 0.25-1.0 mg once daily, with 0.5 mg most studied; it remains investigational and is not FDA-approved.
Figures describe how Tesofensine is reported in the research literature and research-community references — not a recommendation for human use. For laboratory research only.
Dosage protocols
Commonly referenced research tiers. Start conservative; every compound and study context differs.
- Frequency
- Once daily
- Weekly total
- About 1.75 mg/week
- Cycle
- Low end of the Phase 2 obesity dose range
Lowest studied dose in Phase 2 obesity trials.
- Frequency
- Once daily
- Weekly total
- About 3.5 mg/week
- Cycle
- Up to about 24 weeks in Phase 2 trials
The most-studied dose in Phase 2 obesity trials.
- Frequency
- Once daily
- Weekly total
- About 7 mg/week
- Cycle
- Upper end of the Phase 2 obesity dose range
Higher studied dose; investigational context, not a recommendation.
Long half-life, slow accumulation
- Its half-life is about 9 days (roughly 220 hours).
- Daily oral dosing therefore accumulates over days to a steady state.
- Phase 2 obesity trials most studied the 0.5 mg dose.
Investigational, not a peptide
- Not FDA-approved; developed first for neurodegenerative disease, later repurposed for obesity.
- It is a small-molecule monoamine reuptake inhibitor, not a peptide.
Ready to run this protocol?
Dosing is only as good as the vial. Research-grade peptides are third-party tested with published COAs from our top-rated source — reconstitute with confidence and skip the guesswork on identity and purity.
Weekly schedule
A typical week on the standard protocol (Once daily).
Dosing day Off
Handling & storage
- Oral small molecule taken as a tablet, capsule, or oral solution; no reconstitution.
- Its long half-life of about 9 days means blood levels build up over days on daily dosing.
- Trials titrated slowly and capped duration at about 24 weeks.
- Investigational and not FDA-approved.
Tesofensine dosing FAQ
What oral dose did tesofensine trials use?
Phase 2 obesity trials reported roughly 0.25-1.0 mg once daily, with 0.5 mg the most studied dose, for up to about 24 weeks. This is investigational context, not a recommendation.
Why once daily?
Its half-life is about 9 days, so once-daily oral dosing is enough for levels to build to a steady state over time.
Is tesofensine a peptide or an injectable?
Neither. It is an orally active small-molecule triple monoamine reuptake inhibitor taken as a tablet or capsule, not reconstituted or injected.
Is it approved?
No. Tesofensine remains investigational and is not FDA-approved, despite notable weight loss in Phase 2 trials.
Sources
Categories: GLP-1 & Metabolic · Status: Approved (see notes). This page is educational and for laboratory research use only; it is not medical advice.